Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of ixekizumab (Taltz) in the treatment of psoriasis
ChiCTR2000034601Phase 4Recruiting
- Sponsor
- Shanghai Skin Disease Hospital
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ixekizumab in psoriasis, sponsored by Shanghai Skin Disease Hospital. Primary endpoint: Psoriasis Area and Severity Index (PASI). Started Jul 2020; status: recruiting.
02
Drugs
ixekizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on ChiCTR2000034601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034601.